Affiliation:
1. Institute of Biochemistry and Cell Biology (IBBC-CNR), Sapienza University of Rome, Rome, Italy
2. Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
3. Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
4. Department of Sensory Organs, Sapienza University of Rome, Rome, Italy
5. Società Italiana per il Trattamento dell’Alcolismo e le sue Complicanze (SITAC), Rome, Italy
6. Department of Pediatrics, Sapienza University of Rome, Rome, Italy
Abstract
Background and Objective:
This retrospective study aims to disclose further early pa-rameters of COVID-19 morbidity and mortality.
Methods:
Three hundred and eighty-two COVID-19 patients, recruited between March and April 2020, were divided into three groups according to their outcome: (1) hospital ward group (patients who entered the hospital wards and survived); (2) intensive care unit (ICU) group (patients who at-tended the ICU and survived); (3) the deceased group (patients admitted to ICU with a fatal out-come). We investigated routine laboratory parameters such as albumin, glycemia, hemoglobin am-ylase, lipase, AST, ALT, GGT, LDH, CK, MGB, TnT-hs, IL-6, ferritin, CRP, PCT, WBC, RBC, PLT, PT, INR, APTT, FBG, and D-dimer. Blood withdrawal was carried out at the beginning of the hospitalization period.
Results:
ANOVA and ROC data evidenced that the concomitant presence of alterations in albumin, lipase, AST, ALT, LDH, MGB, CK, IL-6, ferritin in women, CRP and D-dimer is an early sign of fatal outcomes.
Conclusion:
The present study confirms and extends the validity of routine laboratory biomarkers (i.e., lipase, AST, ALT, LDH, CK, IL-6, ferritin in women, CRP and D-dimer) as indicators of COVID-19 morbidity and mortality. Furthermore, the investigation suggests that both gross changes in albumin and MGB, markers of liver and heart damage, may early disclose COVID-19 fatal out-comes.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,General Medicine